USD10
SABS Shares
About SAB BiotherapeuticsSAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. The company's candidate, SAB-142 is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of type 1 diabetes (T1D).
USD10
SABS Shares
About SAB BiotherapeuticsSAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. The company's candidate, SAB-142 is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of type 1 diabetes (T1D).
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$191.07M
OPEN PRICE
$3.74
LOW (1Y)
$1.00
HIGH (1Y)
$6.60
LOW (24H)
$3.70
HIGH (24H)
$3.84
VOLUME (24H)
$1.33M
140.38%
Price history
Time | Price | Change |
|---|---|---|
Today | $3.74 | |
1 Day | $3.74 | |
1 Week | $4.35 | |
1 Month | $3.57 | |
1 Year | $1.60 |
Discover more
Popular price predictions
Legal
All securities and investments are offered by Coinbase Capital Markets Corp, member FINRA/SIPC. Securities services offered by Coinbase Capital Markets Corp are separate from digital asset services provided by Coinbase Inc., and any affiliates or crypto asset services provided under MiCA by Coinbase Luxembourg S.A. SIPC does not apply to digital assets or cash held in your Coinbase Inc. account. Additional information about your broker, Coinbase Capital Markets Corp, can be found on FINRA’s BrokerCheck. Execution, clearing and custody of all securities are provided by Apex Clearing Corporation.This page and the content herein is for informational purposes only and does not constitute the provision of investment advice. The customer assumes full responsibility for its trading activity and should consult its advisors for its specific situation. This material is not (i) an offer, or solicitation of an offer, to invest in, or to buy or sell, any interests or shares, or to participate in any investment or trading strategy, (ii) intended to provide accounting, legal, or tax advice, or investment recommendations. The information is believed to be current as of the date indicated and may not be updated or otherwise revised to reflect information that subsequently became available or a change in circumstances after the date of publication. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. Recipients should consult their advisors before making any investment decision.All ticker names are trademarks of their respective holders. Any ticker reference does not imply any affiliation with or endorsement by a third party. Real-time quote and/or trade prices are not sourced from all markets, source: Nasdaq Last Sale. Morningstar data ©2026.
